GMP Best Seller

Recombinant Human KGF/FGF-7 GMP Protein, CF

R&D Systems | Catalog # BT-KGF-GMP

R&D Systems
100% Guarantee

Key Product Details

  • KGF/FGF-7 Manufactured in Bio-Techne's new GMP facility
  • Lot-to-lot consistency
  • Stringent guidelines for patient safety
  • Scalability necessary to support successful therapeutics
  • Learn more about manufacturing in our new GMP facility
  • Test it in your process! Request a sample of GMP KGF
  • A DMF is on file for this protein

Source

E. coli

Accession Number

P21781.1

Applications

Bioactivity
View all KGF/FGF-7 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human KGF/FGF-7 protein
Cys32 - Thr194, with an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.Manufactured and tested under cGMP guidelines.

Purity

>97%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining. The molecular weight by mass spectrometry is 18927 Da ± 61 Da.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

(Cys)32-Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala
Asn33-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr

Predicted Molecular Mass

19 kDa

SDS-PAGE

20 kDa, under reducing conditions.

Activity

Measured in a cell proliferation assay using Ba/F3 mouse pro B cells transfected with human FGF RIIb.
The ED50 for this effect is 6.00-60.0 ng/mL.

The specific activity of recombinant human KGF/FGF-7 is >8.16 x 105 units/mg, which is calibrated against the human KGF/FGF-7 WHO Standard (NIBSC code: 03/150).

Host Cell Protein

<0.500 ng per μg of protein when tested by ELISA.

Mycoplasma

Negative for Mycoplasma.

Host Cell DNA

<0.00150 ng per µg of protein when tested by PCR.

Scientific Data Images for Recombinant Human KGF/FGF-7 GMP Protein, CF

Recombinant Human KGF/FGF‑7 GMP Protein Bioactivity.

The bioactivity of Recombinant Human KGF/FGF‑7 GMP Protein (Catalog # BT-KGF-GMP) was measured in a cell proliferationassay using Ba/F3 mouse pro B cells transfected with human FGF RIIb. The ED50 for this effect is 6.00 ‑ 60.0 ng/mL. Threeindependent lots were tested for bioactivity and plotted on the same graph to show lot-to-lotconsistency of GMP KGF/FGF‑7 protein.

Equivalent Bioactivity of GMPand Animal-Free grades ofRecombinant Human KGF/FGF-7.

Equivalent bioactivity of GMP(Catalog # BT-KGF-GMP) andAnimal-Free (BT-KGF-AFL) grades of RecombinantHuman KGF/FGF-7 measured in a cell proliferationassay using Ba/F3 mouse pro Bcells transfected with human FGFRIIb (orange and green, respectively).

Recombinant Human KGF/FGF‑7 GMP Protein SDS-PAGE.

2 μg/lane of Recombinant Human KGF/FGF‑7 GMP Protein (Catalog # BT-KGF-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 20 kDa, under reducing conditions.

All KGF lots support the differentiation of iPSC to pancreatic progenitor cells.

Characterization of the pancreatic progenitor cells differentiated from iPSCs using different grades of Recombinant Human KGF Protein (Catalog # BT-KGF, BT-KGF-AFL, and BT-KGF-GMP). The iPSC cells (1210a cell line) were cultured in a 24-well plate and differentiated into pancreatic progenitor cells using different lots of KGF and other differentiation factors. Expression of pancreatic progenitor markers was analyzed via flow cytometry with anti-PDX-1 (Catalog # MAB2419) and anti-NKX6.1 antibodies. The PDX-1+/NKX6.1+ double positive cell population was quantified as the pancreatic progenitor cells. The data is represented as the average of three technical replicates.

Pancreatic progenitor cells can be further differentiated into beta islets.

Characterization of the endocrine cells and beta islets differentiated from iPSCs using Recombinant Human KGF/FGF-7 GMP Protein (Catalog # BT-KGF-GMP). A) Brightfield images of the endocrine cells and beta islets. GMP KGF was used for further differentiation of the pancreatic progenitor cells first into endocrine cells and then beta islets. The endocrine cells and beta islets were imaged with an EVOS Cell Imaging System. B) The expression of beta islet markers was analyzed via flow cytometry with anti-NKX6.1 and anti-C-peptide antibodies. The C-peptide+/NKX6.1+ double positive cell population was quantified as the target beta cells. The data is represented as the average of three technical replicates.​

Immunofluorescent imaging shows expression of beta islet markers.

Immunofluorescent images of the beta islets generated using Recombinant Human KGF/FGF-7 GMP Protein (Catalog # BT-KGF-GMP). Beta islets differentiated from iPSCs were fixed, frozen and sectioned. Sections were stained with the anti-C-peptide antibody (Catalog # MAB14171) and the anti-somatostatin antibody (Catalog # MAB2358), followed by the secondary antibody staining (anti-mouse IgG NL493-conjugated antibody: Catalog # NL009; anti-rat IgG NL557-conjugated antibody: Catalog # NL013). A Leica THUNDER Imaging System was utilized for the imaging of C-peptide and somatostatin expression in the beta islets. GMP KGF successfully differentiates the iPSCs into functional beta islets capable of expressing these characteristic markers.

Beta islet cells derived using GMP KGF are functional.

The insulin secretion function of the iPSC-derived beta islets was tested in a glucose-stimulated insulin secretion assay using the Ella™ Automated ELISA platform, and the cell culture supernatant was analyzed with the Ella™ Automated ELISA platform and Simple Plex human insulin cartridge (Catalog # SPCKC-CS-008554). After the incubation of beta islets with 20 mM glucose for 1 hour at 37 °C, the beta islets generated using Recombinant Human KGF/FGF-7 GMP Protein (Catalog # BT-KGF-GMP) were shown to secrete insulin. The data is represented as the average of three technical replicates.

Formulation, Preparation, and Storage

BT-KGF-GMP
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4 and EDTA with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in sterile water.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: KGF/FGF-7

Keratinocyte Growth Factor (KGF), or Fibroblast Growth Factor-7 (FGF-7), is an important component in many cell culture protocols. It is widely used to promote the growth and differentiation of epithelial cells, including skin keratinocytes, and lung, corneal, and intestinal epithelia. It is a part of tissue engineering and organoid culture protocols, where it can enhance the generation of complex tissues such as liver, gastrointestinal tract, lung, and mammary gland. Furthermore, KGF/FGF-7 has been shown to stimulate the proliferation of pancreatic endocrine progenitor cells and promote their differentiation into mature insulin-secreting beta cells. In these capacities KGF/FGF-7 has significant clinical relevance in studies to better understand gastrointestinal disorders, wound healing, respiratory disease, and diabetes.

Long Name

Keratinocyte Growth Factor

Alternate Names

FGF-7, FGF7, HBGF-7, HBGF7

Entrez Gene IDs

2252 (Human); 403915 (Canine)

Gene Symbol

FGF7

UniProt

P21781.1

Additional KGF/FGF-7 Products

Product Documents for Recombinant Human KGF/FGF-7 GMP Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Manufacturing Specifications

GMP Proteins
R&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.

R&D Systems' quality focus includes:

  • Designed, manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
  • Documented and controlled manufacturing process
  • Control of documentation and process changes by QA
  • Personnel training programs
  • Raw material inspection and vendor qualification/monitoring program
  • Validated equipment, processes and test methods
  • Equipment calibration and maintenance schedules using a Regulatory Asset Manager
  • Facility/Utilities maintenance, contamination controls, safety and pest control programs
  • Material review process for variances
  • Robust product stability program following relevant ICH guidelines

R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their application. Each product is provided with a lot-specific Certificate of Analysis that contains the product's specifications and test results. Quality control testing may include, but is not limited to:

  • N-terminal amino acid analysis
  • SDS-PAGE purity analysis
  • Molecular weight analysis via mass spectrometry
  • Endotoxin assessment per USP <85> and Ph. Eur. 2.6.14 guidelines
  • Bioassay analysis
  • Microbial testing per USP <71> and Ph. Eur. 2.6.1 guidelines
  • Host cell protein assessment
  • Host cell DNA assessment
  • Mycoplasma assessment

Additional testing and documentation requested by the customer can be arranged at an additional cost. 

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis and St. Paul, Minnesota USA.

R&D Systems sells GMP grade products for preclinical or clinical ex vivo use. They are not for in vivo use. Please read the following End User Terms prior to using this product.


Animal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.

Production

  • All molecular biology procedures use animal-free media and dedicated labware.
  • Dedicated fermentors are utilized in committed animal-free areas.

Purification

  • Protein purification columns are animal-free.
  • Bulk proteins are filtered using animal-free filters.
  • Purified proteins are stored in animal-free containers.

    Please read our complete Animal-Free Statement

    Product Specific Notices for Recombinant Human KGF/FGF-7 GMP Protein, CF

    Full terms and conditions of sale can be found online in the Protein Sciences Segment T&Cs at: Terms & Conditions.

    For preclinical, or clinical ex vivo use

    Related Research Areas

    FGF Family
    FGF Ligands
    gamma delta T Cells

    Customer Reviews for Recombinant Human KGF/FGF-7 GMP Protein, CF

    There are currently no reviews for this product. Be the first to review Recombinant Human KGF/FGF-7 GMP Protein, CF and earn rewards!

    Have you used Recombinant Human KGF/FGF-7 GMP Protein, CF?

    Submit a review and receive an Amazon gift card!

    $25/€18/£15/$25CAN/¥2500 Yen for a review with an image

    $10/€7/£6/$10CAN/¥1110 Yen for a review without an image

    Submit a review
    Amazon Gift Card

    FAQs

    No product specific FAQs exist for this product.

    View all FAQs for Proteins and Enzymes